Education
About Us
Working with TipRanks
Follow Us
Kainos Laboratories, Inc. (JP:4556)
:4556
RESEARCH TOOLSreports
Top Page
Kainos Laboratories, Inc.
(4556)
Rating:84Outperform
Price Target:
¥1,442.00
▲(16.57%Upside)
Kainos Laboratories, Inc. (4556) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.06B
Dividend Yield2.6%
Average Volume (3M)1.08K
Price to Earnings (P/E)8.1
Beta (1Y)0.21
Revenue Growth4.93%
EPS Growth-0.26%
CountryJP
Employees133
SectorHealthcare
Sector Strength39
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)35.79
Shares Outstanding4,558,860
10 Day Avg. Volume1,380
30 Day Avg. Volume1,076
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kainos Laboratories, Inc. Business Overview & Revenue Model
Company DescriptionKainos Laboratories, Inc. (4556) is a pharmaceutical company that operates in the healthcare sector, specializing in the development, production, and marketing of a wide range of pharmaceutical products. The company focuses on creating innovative drugs and therapies aimed at improving patient outcomes and addressing unmet medical needs. Kainos Laboratories is committed to research and development, leveraging advanced technologies to bring effective solutions to the market.
How the Company Makes MoneyKainos Laboratories, Inc. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue streams include direct sales to healthcare providers, hospitals, and pharmacies, as well as distribution partnerships with other pharmaceutical companies. Additionally, Kainos Laboratories may engage in licensing agreements and collaborative research projects, which can provide additional income through royalties and milestone payments. The company's earnings are influenced by factors such as the successful development and approval of new drugs, market demand for its products, and strategic partnerships that expand its market reach.
Kainos Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.06B | 4.92B | 4.61B | 4.26B | 4.61B |
| Gross Profit | 2.55B | 2.51B | 2.41B | 2.31B | 2.32B |
| EBITDA | 1.05B | 994.26M | 924.87M | 763.42M | 743.08M |
| Net Income | 637.97M | 568.17M | 512.33M | 417.40M | 398.57M |
Balance Sheet | |||||
| Total Assets | 8.59B | 8.12B | 7.57B | 6.96B | 6.74B |
| Cash, Cash Equivalents and Short-Term Investments | 3.17B | 3.02B | 2.68B | 2.24B | 1.96B |
| Total Debt | 862.97M | 941.10M | 947.61M | 1.00B | 1.01B |
| Total Liabilities | 2.32B | 2.45B | 2.37B | 2.30B | 2.36B |
| Stockholders Equity | 6.27B | 5.67B | 5.20B | 4.66B | 4.38B |
Cash Flow | |||||
| Free Cash Flow | 354.87M | 536.81M | 463.19M | 518.06M | 623.06M |
| Operating Cash Flow | 430.58M | 544.51M | 604.36M | 591.25M | 678.18M |
| Investing Cash Flow | -72.83M | -10.33M | -141.19M | -117.16M | -52.20M |
| Financing Cash Flow | -203.73M | -191.14M | -31.25M | -194.61M | 385.76M |
Kainos Laboratories, Inc. Technical Analysis
Positive
1237.00
Price Trends
1231.08
Positive
1209.86
Positive
1189.57
Positive
Market Momentum
1.92
Positive
50.66
Neutral
61.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4556, the sentiment is Positive. The current price of 1237 is below the 20-day moving average (MA) of 1238.75, above the 50-day MA of 1231.08, and above the 200-day MA of 1189.57, indicating a neutral trend. The MACD of 1.92 indicates Positive momentum. The RSI at 50.66 is Neutral, neither overbought nor oversold. The STOCH value of 61.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4556.
Kainos Laboratories, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | ¥5.06B | 8.14 | 2.60% | 4.93% | -0.26% | ||
76 Outperform | ¥121.62B | 20.15 | 2.59% | 11.54% | -8.30% | ||
76 Outperform | ¥5.84B | 7.48 | 1.83% | 8.60% | 33.64% | ||
66 Neutral | ¥14.41B | 13.19 | 3.15% | 2.58% | -53.08% | ||
61 Neutral | ¥70.51B | 16.26 | 3.14% | 15.55% | 42.14% | ||
56 Neutral | ¥10.53B | 118.63 | 3.94% | 6.83% | ― | ||
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% |
* Healthcare Sector Average
Performance Comparison
JP:4556
Kainos Laboratories, Inc.
1,228.00
80.62
7.03%
JP:7702
JMS Co., Ltd.
434.00
-81.01
-15.73%
JP:7730
Mani, Inc.
1,227.50
-698.71
-36.27%
JP:7743
Seed Co., Ltd.
474.00
-87.58
-15.60%
JP:7979
Shofu Inc.
1,948.00
-454.14
-18.91%
JP:7980
Shigematsu Works Co., Ltd.
840.00
77.13
10.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.